POCI

Business Context and Reporting Period

Precision Optics Corporation, Inc. (PEYE) filed its Form 10-Q for the quarterly period ended March 31, 2010. The company designs and manufactures advanced optical instruments, including micro-optics, medical instruments (laparoscopes, arthroscopes, endoscopes), and 3-D endoscopes for minimally invasive surgery. The company is classified as a smaller reporting company and has sustained recurring net losses and negative cash flows from operations for several years, raising substantial doubt about its ability to continue as a going concern.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 5.1% for the quarter and 14.2% for the nine-month period compared to the prior year. This was primarily due to lower unit volume sales of optical components, couplers, and endoscopes, partially offset by higher sales of an advanced surgical visualization system.
• Gross Margin Improvement (Quarterly): Gross profit margin increased to 43.1% from 36.7% in the prior year quarter, driven by manufacturing efficiencies and lower fixed overhead. However, the nine-month margin decreased to 38.2% from 44.6% due to lower overall sales volume.
• Expense Reductions: Research and Development (R&D) expenses dropped 35.1% for the quarter and 37.0% for the nine months, attributed to cost containment plans and increased customer reimbursements for development activities. Selling, General, and Administrative (SG&A) expenses decreased 1.4% for the quarter and 14.1% for the nine months.
• Interest Expense: Interest expense for the nine months decreased 50.0% to $194,625 from $388,925 in the prior year, due to the discontinuation of amortization of the debt discount related to the conversion feature of the Senior Secured Convertible Notes.
• Customer Concentration: Customer A increased its share of revenue to 27% from 16% in the prior nine-month period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management states that operating losses are expected to continue through fiscal year 2010 until sales reach breakeven levels. The company anticipates settling approximately $508,000 of deferred officer salaries and director consulting expenses via restricted stock rather than cash.
• Debt Maturity Risk: The 10% Senior Secured Convertible Notes (principal $600,000 plus accrued interest) mature on June 25, 2010. Management notes it is highly unlikely the company can generate sufficient cash to repay this in full if holders do not convert to equity. The company is exploring refinancing or renegotiation.
• Product Outlook: The company is focusing on commercializing new technologies, including Lenslock endoscopes and micro-precision lenses. R&D reimbursements are expected to exceed $0.5 million for the full fiscal year 2010.
• Internal Controls: The company identified material weaknesses in internal controls regarding segregation of duties (due to limited accounting staff) and inventory valuation. Remediation efforts include higher-level reviews by the Board and improved inventory documentation.
• Unusual Items: The company recorded a gain of $17,612 on the sale of previously written-off assets during the nine-month period.

Investor Verification Checklist

• Verify the status of the $600,000 Senior Secured Convertible Notes maturing June 25, 2010, and whether holders have elected to convert to equity.
• Confirm the company's ability to generate sufficient cash flow or secure financing to meet the $727,600 in contractual cash commitments due in fiscal year 2010.
• Monitor the effectiveness of cost containment measures and the realization of projected R&D reimbursements exceeding $0.5 million.
• Assess the progress of remediation for material weaknesses in internal controls over financial reporting.
• Review the concentration risk associated with Customer A, which accounted for 27% of revenues in the first nine months of 2010.